Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4765-4771

  Poissy, Julien ^a,d   Aubry, Alexandra ^a,b,c   Fernandez, Christine ^b   Lott, Marie Catherine ^b   Chauffour, Aurelie ^a   Jarlier, Vincent ^a,b,c   Farinotti, Robert ^b   Veziris, Nicolas ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WILD TYPE;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DNA GYRASE; ENOXACIN; FLUOROQUINOLONES; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 78049250845     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00968-10     Document Type: Article

References (48)

1. Aubry, A., X. S. Pan, L. M. Fisher, V. Jarlier, and E. Cambau. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288.
2. Aubry, A., N. Veziris, E. Cambau, C. Truffot-Pernot, V. Jarlier, and L. M. Fisher. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
3. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, P. Moine, C. Cherbuliez, G. Peytavin, B. Fantin, and T. Kohler. 2005. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob. Agents Chemother. 49:1046-1054.
4. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
5. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
6. Centers for Disease Control and Prevention. 2007. Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR Morb. Mortal. Wkly. Rep. 56:250-253.
7. Centers for Disease Control and Prevention. 2009. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recommend. Rep. 58:1-43.
8. Chan, E. D., V. Laurel, M. J. Strand, J. F. Chan, M. L. Huynh, M. Goble, and M. D. Iseman. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169:1103-1109.
9. Chiang, C. Y., D. A. Enarson, M. C. Yu, K. J. Bai, R. M. Huang, C. J. Hsu, J. Suo, and T. P. Lin. 2006. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur. Respir. J. 28:980-985.
10. Codecasa, L. R., G. Ferrara, M. Ferrarese, M. A. Morandi, V. Penati, C. Lacchini, P. Vaccarino, and G. B. Migliori. 2006. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med. 100:1566-1572.
11. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
12. Conde, M. B., A. Efron, C. Loredo, G. R. De Souza, N. P. Graca, M. C. Cezar, M. Ram, M. A. Chaudhary, W. R. Bishai, A. L. Kritski, and R. E. Chaisson. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
13. Dorman, S. E., J. L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C. M. Heilig, J. Bernardo, S. Choudhri, J. H. Grosset, E. Guy, P. Guyadeen, M. C. Leus, G. Maltas, D. Menzies, E. L. Nuermberger, M. Villarino, A. Vernon, and R. E. Chaisson. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
14. Duong, D. A., T. H. Nguyen, T. N. Nguyen, V. H. Dai, T. M. Dang, S. K. Vo, D. A. Do, V. V. Nguyen, H. D. Nguyen, N. S. Dinh, J. Farrar, and M. Caws. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839.
15. Dye, C. 2006. Global epidemiology of tuberculosis. Lancet 367:938-940.
16. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, and M. C. Raviglione. 2001. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 344:1294-1303.
17. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
18. Grosset, J., and B. Ji. 1998. Experimental chemotherapy of mycobacterial diseases, p. 51-97. In P. R. Gandharam and P. Jenkins (ed.), Mycobacteria. Marcel Dekker, New York, NY.
19. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
20. Johnson, C. N., D. E. Briles, W. H. Benjamin, Jr., S. K. Hollingshead, and K. B. Waites. 2005. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg. Infect. Dis. 11:814-820.
21. Kam, K. M., C. W. Yip, T. L. Cheung, H. S. Tang, O. C. Leung, and M. Y. Chan. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11.
22. Keshavjee, S., I. Y. Gelmanova, P. E. Farmer, S. P. Mishustin, A. K. Strelis, Y. G. Andreev, A. D. Pasechnikov, S. Atwood, J. S. Mukherjee, M. L. Rich, J. J. Furin, E. A. Nardell, J. Y. Kim, and S. S. Shin. 2008. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372:1403-1409.
23. Kliiman, K., and A. Altraja. 2009. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur. Respir. J. 33:1085-1094.
24. Kocagoz, T., C. J. Hackbarth, I. Unsal, E. Y. Rosenberg, H. Nikaido, and H. F. Chambers. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774.
25. Levine, C., H. Hiasa, and K. J. Marians. 1998. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400:29-43.
26. Lubasch, A., I. Keller, K. Borner, P. Koeppe, and H. Lode. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
27. Luo, N., S. Pereira, O. Sahin, J. Lin, S. Huang, L. Michel, and Q. Zhang. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci. U. S. A. 102:541-546.
28. Masjedi, M. R., P. Farnia, S. Sorooch, M. V. Pooramiri, S. D. Mansoori, A. Z. Zarifi, A. Akbarvelayati, and S. Hoffner. 2006. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin. Infect. Dis. 43:841-847.
29. Mitnick, C. D., S. S. Shin, K. J. Seung, M. L. Rich, S. S. Atwood, J. J. Furin, G. M. Fitzmaurice, F. A. Alcantara Viru, S. C. Appleton, J. N. Bayona, C. A. Bonilla, K. Chalco, S. Choi, M. F. Franke, H. S. Fraser, D. Guerra, R. M. Hurtado, D. Jazayeri, K. Joseph, K. Llaro, L. Mestanza, J. S. Mukherjee, M. Munoz, E. Palacios, E. Sanchez, A. Sloutsky, and M. C. Becerra. 2008. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359:563-574.
30. Miyazaki, E., M. Miyazaki, J. M. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:85-89.
31. Rosenthal, I. M., K. Williams, S. Tyagi, A. A. Vernon, C. A. Peloquin, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2005. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 172:1457-1462.
32. Ruiz, J. 2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51:1109-1117.
33. Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Sturm, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, and D. A. Mitchison. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuber. Lung Dis. 12:128-138.
34. Sanger, F., S. Nicklen, and A. R. Coulson. 1992. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology 24:104-108.
35. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
36. Siefert, H. M., A. Domdey-Bette, K. Henninger, F. Hucke, C. Kohlsdorfer, and H. H. Stass. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43(Suppl. B):69-76.
37. Stass, H., and A. Dalhoff. 2005. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 33(Suppl. 2):29-35. (Pubitemid 43151376)
38. Tahaoglu, K., T. Torun, T. Sevim, G. Atac, A. Kir, L. Karasulu, I. Ozmen, and N. Kapakli. 2001. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345:170-174.
39. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
40. van den Boogaard, J., G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse. 2009. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 53:849-862.
41. Veziris, N., C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 47:3117-3122.
42. Wang, J. Y., L. N. Lee, H. C. Lai, S. K. Wang, I. S. Jan, C. J. Yu, P. R. Hsueh, and P. C. Yang. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother. 59:860-865.
43. Williams, B., and D. Maher. 2007. Tuberculosis fueled by HIV: putting out the flames. Am. J. Respir. Crit. Care Med. 175:6-8.
44. Wise, R., J. M. Andrews, G. Marshall, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43:1508-1510.
45. World Health Organization. 2006. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly. Epidemiol. Rec 81:430-432.
46. World Health Organization. 2001. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for dots-plus. World Health Organization, Geneva, Switzerland.
47. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
48. Zignol, M., M. S. Hosseini, A. Wright, C. L. Weezenbeek, P. Nunn, C. J. Watt, B. G. Williams, and C. Dye. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.